日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

CER818: A Highly Specific and Sensitive HPV L1 High-Risk Serological Lateral Flow Rapid Test for Early Detection of Cervical Cancer and Its Precursor Lesions

CER818:一种高特异性和高灵敏度的HPV L1高危血清学侧向层析快速检测方法,用于早期检测宫颈癌及其癌前病变

Bräutigam, Karen; Meier, Stefanie; Köster, Frank; Rody, Achim; Hilfrich, Ralf

Human Papillomavirus Type 16 L1 Serological Test Shows High Concordance with Anal Cytology in People Living with HIV

人乳头瘤病毒16型L1血清学检测与HIV感染者的肛门细胞学检查结果高度一致

Ecke, Sara; Huber, Anna; Hilfrich, Ralf; French, Lars; Reinholz, Markus

Outcomes in Critically Ill Patients Sedated with Intravenous Lormetazepam or Midazolam: A Retrospective Cohort Study

静脉注射氯美他泮或咪达唑仑镇静危重患者的预后:一项回顾性队列研究

Weiss, Björn; Hilfrich, David; Vorderwülbecke, Gerald; Heinrich, Maria; Grunow, Julius J; Paul, Nicolas; Kruppa, Jochen; Neuner, Bruno; Drexler, Berthold; Balzer, Felix; Spies, Claudia D

Guideline-conform translation and cultural adaptation of the Addenbrooke's Cognitive Examination III into German

将艾登布鲁克认知检查III进行符合指南的翻译和文化适应性调整,使其达到德语水平。

Weiss, Björn; Grunow, Julius J; Rosenthal, Max; Hilfrich, David; Mörgeli, Rudolf; Neuner, Bruno; Borchers, Friedrich; Kraft, Antje; Krampe, Henning; Denke, Claudia; Spies, Claudia D

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study

BRCA1/2 突变和贝伐单抗在乳腺癌新辅助治疗中的应用:来自 GeparQuinto 研究的三阴性乳腺癌患者的疗效和预后结果

Fasching, Peter A; Loibl, Sibylle; Hu, Chunling; Hart, Steven N; Shimelis, Hermela; Moore, Raymond; Schem, Christian; Tesch, Hans; Untch, Michael; Hilfrich, Jörn; Rezai, Mahdi; Gerber, Bernd; Costa, Serban Dan; Blohmer, Jens-Uwe; Fehm, Tanja; Huober, Jens; Liedtke, Cornelia; Weinshilboum, Richard M; Wang, Liewei; Ingle, James N; Müller, Volkmar; Nekljudova, Valentina; Weber, Karsten E; Rack, Brigitte; Rübner, Matthias; von Minckwitz, Gunter; Couch, Fergus J

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

21基因复发评分检测会影响ER阳性、淋巴结阴性和淋巴结阳性早期乳腺癌的辅助治疗建议,从而导致化疗方案根据风险进行调整。

Eiermann, W; Rezai, M; Kümmel, S; Kühn, T; Warm, M; Friedrichs, K; Schneeweiss, A; Markmann, S; Eggemann, H; Hilfrich, J; Jackisch, C; Witzel, I; Eidtmann, H; Bachinger, A; Hell, S; Blohmer, J

Sequences of complete human cytomegalovirus genomes from infected cell cultures and clinical specimens

从感染细胞培养物和临床标本中获得的人类巨细胞病毒完整基因组序列

Cunningham, Charles; Gatherer, Derek; Hilfrich, Birgitta; Baluchova, Katarina; Dargan, Derrick J; Thomson, Marian; Griffiths, Paul D; Wilkinson, Gavin W G; Schulz, Thomas F; Davison, Andrew J

Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer)

苏黎世共识:德国专家对2009年3月15日圣加仑投票结果的意见(第11届圣加仑国际会议:早期乳腺癌的一线治疗)

Beckmann, Matthias W; Blohmer, Jens-Uwe; Costa, Serban-Dan; Diedrich, Klaus; Diel, Ingo; Eiermann, Wolfgang; Friese, Klaus; Gerber, Bernd; Harbeck, Nadia; Hilfrich, Joern; Janni, Wolfgang; Jaenicke, Fritz; Jonat, Walter; Kaufmann, Manfred; Kiechle, Marion; Koehler, Uwe; Kreienberg, Rolf; von Minckwitz, Gunter; Moebus, Volker; Nitz, Ulrike; Schneeweiss, Andreas; Thomssen, Christoph; Wallwiener, Diethelm